Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients with moderate to severe plaque type psoriasis for at least 6 months before randomization~* patients eligible for systemic therapy with inadequately controlled psoriasis~Exclusion Criteria:~* forms of sporiasis other than plaque type psoriasis~* previous exposure to secukinumab, ustekinumab, or other biologic drugs targeting (IL)-17A or IL-17RA~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AIN457 300 mg (Type: EXPERIMENTAL): patients received AIN457 (secukinumab) 300 mg (two secukinumab 150 mg injections) s.c. (subcutaneously) once every week at weeks 0, 1,2,3, followed by monthly dosing starting at week 4 to week 48 inclusive
- Ustekinumab (Type: ACTIVE_COMPARATOR): patients received ustekinumab 45/90 mg (weight depended, according to label) s.c. (subcutaneously) and/or placebo secukinumab injections once every week at weeks 0,1,2, and 3 followed by monthly dosing starting at week 4 to week 48 inclusive

Based on this trial design, predict the completion outcome and termination type (if applicable).